- Home
- IBRX
IBRX
ImmunityBio Inc.
as of 01-26-2026 3:40pm EST
$6.23
$0.33
-4.96%
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 2.6B | IPO Year: | N/A |
| Target Price: | $11.80 | AVG Volume (30 days): | 46.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.83 - $8.28 | Next Earning Date: | 03-02-2026 |
| Revenue: | $82,555,000 | Revenue Growth: | 1025.95% |
| Revenue Growth (this year): | 680.06% | Revenue Growth (next year): | 90.18% |
AI-Powered IBRX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 0.00%
0.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of ImmunityBio Inc. (IBRX)
Simon Barry J.
Sell
Director
IBRX Jan 20, 2026
Avg Cost/Share
$7.21
Shares
151,967
Total Value
$1,094,296.68
Owned After
3,166,604
Selecky Christobel
Sell
Director
IBRX Jan 20, 2026
Avg Cost/Share
$7.51
Shares
25,000
Total Value
$187,650.00
Owned After
0
SEC Form 4
Selecky Christobel
Sell
Director
IBRX Jan 16, 2026
Avg Cost/Share
$5.00
Shares
50,000
Total Value
$250,000.00
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Simon Barry J. | IBRX | Director | Jan 20, 2026 | Sell | $7.21 | 151,967 | $1,094,296.68 | 3,166,604 | |
| Selecky Christobel | IBRX | Director | Jan 20, 2026 | Sell | $7.51 | 25,000 | $187,650.00 | 0 | |
| Selecky Christobel | IBRX | Director | Jan 16, 2026 | Sell | $5.00 | 50,000 | $250,000.00 | 0 |
Latest ImmunityBio Inc. News
IBRX Breaking Stock News: Dive into IBRX Ticker-Specific Updates for Smart Investing
Associated Press Finance
BC-Most Active Stocks
Insider Monkey
Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That”
➖
AI Sentiment
Neutral
5/10
Motley Fool
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
📈
AI Sentiment
Highly Positive
8/10
Zacks
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
📈
AI Sentiment
Highly Positive
9/10
Compare IBRX vs Leading Stocks
See how IBRX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IBRX ImmunityBio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.